Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems

Hepatology Research

Volumn 40, Issue 11, 2010, Pages 1082-1091

  Kawaoka, Tomokazu ^a   Aikata, Hiroshi ^a   Takaki, Shintaro ^a   Hashimoto, Yoshimasa ^a   Katamura, Yoshio ^a   Hiramatsu, Akira ^a   Waki, Koji ^a   Takahashi, Shoichi ^a   Kamada, Koji ^b   Kitamoto, Mikiya ^c   Nakanishi, Toshio ^d   Ishikawa, Masaki ^a   Hieda, Masashi ^a   Kakizawa, Hideaki ^a   Tanaka, Junko ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Shobara Red Cross Hospital   (Japan)

^c HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^d Miyoshi Central Hospital   (Japan)

Author keywords

Akaike's information criterion; Chemoembolization; Cisplatin; Hepatocellular carcinoma; Staging systems

Indexed keywords

CISPLATIN; IODINATED POPPYSEED OIL; LIPIODOL ULTRAFLUIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BARCELONA STAGE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; ITALIAN SCORE; JAPAN INTEGRATED STAGING SCORE; LIVER CANCER STUDY GROUP OF JAPAN TUMOR NODE METASTASIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MODIFIED JAPAN INTEGRATED STAGING; OVERALL SURVIVAL; PORTAL VEIN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; THERAPY EFFECT; TUMOR THROMBUS;

EID: 77958595683     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00714.x     Document Type: Article

References (50)

1. Okita K. Management of hepatocellular carcinoma in Japan. J Gastroenterol 2006; 41: 100-6.
2. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-3.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
4. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35: S72-8.
5. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
6. Livraghi T, Festi D, Monti F, Salmi A, Vettori C. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. Radiology 1986; 161: 309-12.
7. Seki T, Wakabayashi M, Nakagawa T et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994; 1: 817-25.
8. Amin Z, Donald JJ, Masters A et al. Hepatic metastases: interstitial laser photocoagulation with real-time US monitoring and dynamic CT evaluation of treatment. Radiology 1993; 187: 339-47.
9. Rossi S, Buscarini E, Garbagnati F et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol 1998; 170: 1015-22.
10. Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol 2001; 11: 914-21.
11. Saneto H, Kobayashi M, Kawamura Y et al. Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients. J Gastroenterol 2008; 43: 975-81.
12. Miki D, Aikata H, Uka K et al. Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol 2008; 43: 550-7.
13. Noda I, Kitamoto M, Nakahara H et al. Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 2010; 5: 105-12.
14. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401.
15. Kamada K, Nakanishi T, Kitamoto M et al. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 2001; 12: 847-54.
16. Kawaoka T, Aikata H, Takaki S et al. Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 2009; 32: 687-94.
17. Ikeda M, Maeda S, Shibata J et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004; 66: 24-31.
18. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 18 (359): 1734-9.
19. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
20. Bruix J, Llovet JM, Castells A et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-83.
21. Pelletier G, Ducreux M, Gay F et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29: 129-34.
22. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
23. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127: S179-88.
24. The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg 1989; 19: 98-129.
25. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207-15.
26. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-5.
27. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
28. Nanashima A, Sumida Y, Morino S et al. The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol 2004; 30: 765-70.
29. Yen YH, Changchien CS, Wang JH et al. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis 2009; 41: 431-41.
30. Guglielmi A, Ruzzenente A, Pachera S et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 2008; 103: 597-604.
31. Huo TI, Lin HC, Hsia CY et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol 2007; 102: 1920-30.
32. Luo KZ, Itamoto T, Amano H et al. Comparative study of the Japan Integrated Stage (JIS) and modified JIS score as a predictor of survival after hepatectomy for hepatocellular carcinoma. J Gastroenterol 2008; 43: 369-77.
33. Testa R, Testa E, Giannini E et al. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther 2003; 15: 1563-9.
34. Kim JH, Choi JH, Kim CH et al. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Scand J Gastroenterol 2009; 44: 346-57.
35. Chuang VP, Wallace S. Hepatic artery embolization in the treatment of hepatic neoplasms. Radiology 1981; 140: 51-8.
36. Ohishi H, Uchida H, Yoshimura H et al. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology 1985; 154: 25-9.
37. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989; 170: 783-6.
38. Takayasu K, Arii S, Matsuo N et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 2000; 175: 699-704.
39. Omagari K, Ohba K, Kadokawa Y et al. Comparison of the grade evaluated by "Liver damage" of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma. Hepatol Res 2006; 34: 266-72.
40. Toyoda H, Kumada T, Kiriyama S et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 2005; 100: 1764-71.
41. Uka K, Aikata H, Takaki S et al. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int 2007; 27: 1209-16.
42. Uka K, Aikata H, Takaki S et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 2007; 42: 845-53.
43. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998; 55: 39-47.
44. Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 15: 435-42.
45. Ota H, Nagano H, Sakon M et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 5: 557-64.
46. Obi S, Yoshida H, Toune R et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 1: 1990-7.
47. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 24): 378-90.
48. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
49. Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 2009; 9: 739-45.
50. Yamamoto K, Shimizu T, Narabayashi I. Intraarterial infusion chemotherapy with lipiodol-CDDP suspension for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2000; 23: 26-39.